Index -
P/E -
EPS (ttm) -
Insider Own 29.61%
Shs Outstand 43.12M
Perf Week -5.71%
Market Cap 648.09M
Forward P/E -
EPS next Y -4.00
Insider Trans 19.27%
Shs Float 30.35M
Perf Month -31.43%
Income -
PEG -
EPS next Q -0.84
Inst Own 3.27%
Short Float 5.13%
Perf Quarter -
Sales -
P/S -
EPS this Y 96.35%
Inst Trans -
Short Ratio 3.08
Perf Half Y -
Book/sh -3.05
P/B -
EPS next Y -22.14%
ROA -
Short Interest 1.56M
Perf Year -
Cash/sh 1.33
P/C 11.26
EPS next 5Y -
ROE -
52W Range 13.96 - 35.06
Perf YTD -49.90%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -
52W High -57.13%
Beta -
Dividend TTM -
Quick Ratio 3.05
Sales past 5Y -37.90%
Gross Margin -
52W Low 7.66%
ATR (14) 1.58
Dividend Ex-Date -
Current Ratio 3.05
EPS Y/Y TTM -
Oper. Margin -
RSI (14) 29.08
Volatility 9.90% 7.83%
Employees 96
Debt/Eq 0.18
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 42.75
Option/Short Yes / Yes
LT Debt/Eq 0.13
EPS Q/Q -
Payout -
Rel Volume 1.07
Prev Close 16.61
Sales Surprise -
EPS Surprise -2819.81%
Sales Q/Q -
Earnings Mar 26 AMC
Avg Volume 504.48K
Price 15.03
SMA20 -25.09%
SMA50 -37.79%
SMA200 -39.68%
Trades
Volume 538,183
Change -9.51%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-04-24 Initiated
Wells Fargo
Overweight
$44
Mar-04-24 Initiated
Morgan Stanley
Overweight
$40
Mar-04-24 Initiated
Leerink Partners
Outperform
$48
Mar-04-24 Initiated
JP Morgan
Overweight
$39
Apr-11-24 05:01PM
Mar-29-24 02:59PM
Mar-26-24 04:05PM
Mar-14-24 07:00AM
(The Wall Street Journal)
Mar-07-24 07:26PM
06:14PM
Loading…
06:14PM
Feb-12-24 04:39PM
Feb-07-24 10:29PM
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Feb 12 '24 Buy 22.00 910,000 20,020,000 4,126,119 Feb 13 05:48 PM Northpond Ventures III GP, LLC Former 10% Owner Feb 12 '24 Buy 22.00 450,000 9,900,000 450,000 Feb 12 05:51 PM Bain Capital Life Sciences Inv 10% Owner Feb 12 '24 Buy 22.00 450,000 9,900,000 3,163,868 Feb 14 05:26 PM Vida Ventures, LLC 10% Owner Feb 12 '24 Buy 22.00 253,136 5,568,992 252,553 Feb 14 07:04 PM
Index RUT
P/E -
EPS (ttm) -1.78
Insider Own 23.69%
Shs Outstand 78.37M
Perf Week 1.53%
Market Cap 424.71M
Forward P/E -
EPS next Y -1.64
Insider Trans 1.47%
Shs Float 69.55M
Perf Month -27.75%
Income -134.24M
PEG -
EPS next Q -0.34
Inst Own 76.64%
Short Float 5.96%
Perf Quarter 9.91%
Sales 0.00M
P/S -
EPS this Y 13.88%
Inst Trans 11.13%
Short Ratio 2.37
Perf Half Y 105.29%
Book/sh 3.20
P/B 1.46
EPS next Y -7.79%
ROA -46.07%
Short Interest 4.14M
Perf Year -4.51%
Cash/sh 2.85
P/C 1.64
EPS next 5Y 38.60%
ROE -55.73%
52W Range 1.57 - 8.40
Perf YTD 2.64%
Dividend Est. -
P/FCF -
EPS past 5Y -29.69%
ROI -47.99%
52W High -44.52%
Beta 1.29
Dividend TTM -
Quick Ratio 14.72
Sales past 5Y 0.00%
Gross Margin -
52W Low 196.82%
ATR (14) 0.46
Dividend Ex-Date -
Current Ratio 14.72
EPS Y/Y TTM 37.91%
Oper. Margin 0.00%
RSI (14) 39.54
Volatility 6.50% 8.03%
Employees 71
Debt/Eq 0.13
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 15.17
Option/Short Yes / Yes
LT Debt/Eq 0.12
EPS Q/Q 24.94%
Payout -
Rel Volume 0.50
Prev Close 4.75
Sales Surprise -
EPS Surprise 17.34%
Sales Q/Q -
Earnings Mar 26 AMC
Avg Volume 1.75M
Price 4.66
SMA20 -10.59%
SMA50 -16.78%
SMA200 24.19%
Trades
Volume 876,459
Change -1.89%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-01-24 Upgrade
JP Morgan
Neutral → Overweight
$11
Dec-21-23 Upgrade
BofA Securities
Neutral → Buy
$4 → $6
Oct-30-23 Initiated
Wells Fargo
Overweight
$11
May-26-23 Downgrade
BofA Securities
Buy → Neutral
$8 → $3
May-25-23 Downgrade
JP Morgan
Overweight → Neutral
$19 → $9
Sep-16-22 Initiated
Jefferies
Buy
$12
Sep-09-22 Initiated
BTIG Research
Buy
$15
Nov-30-21 Initiated
H.C. Wainwright
Buy
$40
Sep-23-21 Initiated
Cantor Fitzgerald
Overweight
$40
Jan-26-21 Initiated
Needham
Buy
$37
Aug-18-20 Initiated
JP Morgan
Overweight
$33
Aug-18-20 Initiated
Cowen
Outperform
Aug-18-20 Initiated
BofA Securities
Buy
$33
Show Previous Ratings
May-01-24 10:15AM
08:00AM
Apr-25-24 09:35AM
Apr-17-24 09:40AM
Apr-16-24 04:05PM
09:00AM
Loading…
09:00AM
Apr-14-24 12:52PM
Apr-10-24 06:15PM
Apr-03-24 08:00AM
Apr-01-24 12:00PM
09:55AM
Mar-28-24 05:31AM
Mar-26-24 08:53PM
04:05PM
Mar-18-24 04:05PM
08:40AM
Loading…
Mar-14-24 08:40AM
Mar-12-24 02:51PM
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-20-24 04:05PM
Feb-13-24 01:10PM
Jan-18-24 09:40AM
Jan-17-24 11:06AM
Jan-07-24 08:00PM
Dec-27-23 06:30AM
Dec-20-23 05:27PM
05:10PM
05:08PM
Dec-18-23 04:01PM
Nov-22-23 04:01PM
07:20PM
Loading…
Nov-14-23 07:20PM
Nov-13-23 06:30AM
Nov-09-23 06:30AM
Oct-24-23 06:30AM
Oct-18-23 04:01PM
Oct-10-23 06:30AM
Sep-19-23 06:30AM
Sep-18-23 04:01PM
Sep-08-23 09:35AM
Aug-07-23 06:30AM
Aug-02-23 04:01PM
Jul-30-23 12:00PM
Jul-27-23 06:30AM
Jul-24-23 06:30AM
Jun-14-23 08:36AM
May-30-23 10:40AM
May-26-23 03:05AM
May-25-23 11:52AM
10:12AM
May-24-23 04:01PM
May-16-23 04:01PM
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
Jan-04-23 06:30AM
Dec-01-22 09:55AM
Nov-21-22 06:13AM
Nov-17-22 04:01PM
Nov-15-22 09:55AM
Nov-03-22 06:30AM
Oct-18-22 04:01PM
Oct-11-22 07:01AM
Sep-16-22 04:01PM
Sep-01-22 05:56PM
(American City Business Journals)
Aug-17-22 04:05PM
Aug-08-22 04:01PM
Jul-11-22 06:25PM
Jul-08-22 07:00AM
Jun-07-22 12:19PM
06:30AM
Jun-02-22 06:30AM
Jun-01-22 07:30AM
May-09-22 04:01PM
May-05-22 06:30AM
Apr-21-22 06:02AM
Apr-18-22 10:35AM
Apr-07-22 06:30AM
Apr-04-22 06:30AM
Mar-03-22 04:01PM
Mar-01-22 04:01PM
Feb-28-22 06:30AM
Jan-20-22 06:30AM
Jan-05-22 05:10PM
06:33AM
Jan-04-22 04:05PM
06:30AM
Dec-31-21 08:30AM
Dec-13-21 09:00AM
Nov-30-21 05:24AM
Nov-28-21 11:17AM
Nov-09-21 04:01PM
Oct-19-21 06:38AM
Oct-04-21 10:49AM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Carson William H. Director Apr 08 '24 Buy 6.07 3,200 19,411 3,200 Apr 10 07:17 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Feb 20 '24 Sale 5.51 2,604 14,348 72,471 Feb 21 04:31 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Feb 20 '24 Sale 5.53 2,593 14,339 82,058 Feb 21 04:31 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Feb 20 '24 Sale 5.48 1,951 10,691 85,641 Feb 21 04:31 PM Love Douglas PRESIDENT AND CEO Feb 12 '24 Sale 5.54 5,782 32,032 196,121 Feb 14 07:56 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Feb 12 '24 Sale 5.54 1,810 10,027 36,075 Feb 14 07:52 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Feb 12 '24 Sale 5.54 1,809 10,022 45,651 Feb 14 07:54 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Feb 12 '24 Sale 5.53 1,349 7,460 48,592 Feb 14 07:59 PM Yednock Ted EVP & Chief Innovation Officer Dec 27 '23 Option Exercise 1.63 21,000 34,176 21,000 Dec 29 04:12 PM Yednock Ted EVP & Chief Innovation Officer Dec 27 '23 Sale 4.52 21,000 94,966 0 Dec 29 04:12 PM Satter Muneer A Director Dec 26 '23 Buy 2.88 350,000 1,008,000 7,406,024 Dec 28 04:30 PM Lew Jennifer EVP & Chief Financial Officer Jul 11 '23 Sale 3.84 1,057 4,055 47,460 Jan 23 04:57 PM Overdorf Michael EVP & Chief Business Officer Jul 11 '23 Sale 3.84 978 3,752 45,802 Jan 23 04:58 PM Bain Capital Life Sciences Inv 10% Owner May 25 '23 Buy 2.13 300,000 639,720 5,701,926 May 30 09:54 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite